Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease
Identifieur interne : 000A58 ( PascalFrancis/Checkpoint ); précédent : 000A57; suivant : 000A59Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease
Auteurs : Joseph H. Friedman [États-Unis] ; Guido Alves [Norvège] ; Peter Hagell [Suède] ; Johan Marinus [Pays-Bas] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni]Source :
- Movement disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Recommandation.
English descriptors
Abstract
Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was "recommended" if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of "recommended" differs from the use of this term in previous MDS task force scale reviews. "Suggested" scales failed to meet all the criteria of a "recommended" scale, usually the criterion of sensitivity to change in a study of PD. Scales were "listed" if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was "recommended" for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is "suggested" for both screening and severity. The Functional Assessment of Chronic Illness Therapy-Fatigue was "recommended" for screening and "suggested" for severity. The Multidimensional Fatigue Inventory was "suggested" for screening and "recommended" for severity. The Parkinson Fatigue Scale was "recommended" for screening and "suggested" for severity rating. The Fatigue Severity Inventory was "listed" for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was "listed" for screening and "suggested" for severity. Visual Analogue and Global Impression Scales are both "listed" for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed.
Affiliations:
- Autriche, Espagne, France, Norvège, Pays-Bas, Portugal, Royaume-Uni, Suède, États-Unis
- Communauté de Madrid, Hollande-Méridionale, Illinois, Maryland, Midi-Pyrénées, Rhode Island, Texas, Tyrol (Land)
- Innsbruck, Leyde, Madrid, Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse, Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:10-0288337Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease</title><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>NeuroHealth, Parkinson's Disease and Movement Disorders Center</s1><s2>Warwick, Rhode Island</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Rhode Island</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, Warren Alpert Medical School, Brown University</s1><s2>Rhode Island</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>The Norwegian Centre for Movement Disorders, Stavanger University Hospital</s1><s2>Stavanger</s2><s3>NOR</s3><sZ>2 aut.</sZ></inist:fA14><country>Norvège</country><wicri:noRegion>Stavanger</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Stavanger University Hospital</s1><s2>Stavanger</s2><s3>NOR</s3><sZ>2 aut.</sZ></inist:fA14><country>Norvège</country><wicri:noRegion>Stavanger</wicri:noRegion></affiliation></author><author><name sortKey="Hagell, Peter" sort="Hagell, Peter" uniqKey="Hagell P" first="Peter" last="Hagell">Peter Hagell</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Lund University Hospital</s1><s2>Lund</s2><s3>SWE</s3><sZ>3 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>Lund</wicri:noRegion></affiliation></author><author><name sortKey="Marinus, Johan" sort="Marinus, Johan" uniqKey="Marinus J" first="Johan" last="Marinus">Johan Marinus</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Neurology, Leiden University Medical Center</s1><s2>Leiden</s2><s3>NLD</s3><sZ>4 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Department of Psychiatry Johns Hopkins Hospital</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Department of Neurology, Johns Hopkins Hospital</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="09"><s1>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1><s2>Madrid</s2><s3>ESP</s3><sZ>6 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><inist:fA14 i1="11"><s1>Department of Neurological Sciences, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innshruck</s2><s3>AUT</s3><sZ>8 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Innshruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>ClinicalInvestigation Center INSERM CIC-9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Lahoratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa</s1><s3>PRT</s3><sZ>10 aut.</sZ></inist:fA14><country>Portugal</country><wicri:noRegion>Lahoratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa</wicri:noRegion></affiliation></author><author><name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name><affiliation wicri:level="2"><inist:fA14 i1="11"><s1>Department of Neurological Sciences, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1><s3>GBR</s3><sZ>12 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Department of Clinical Neurosciences, Institute of Neurology, University College London</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0288337</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0288337 INIST</idno><idno type="RBID">Pascal:10-0288337</idno><idno type="wicri:Area/PascalFrancis/Corpus">000B17</idno><idno type="wicri:Area/PascalFrancis/Curation">002202</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000A58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease</title><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>NeuroHealth, Parkinson's Disease and Movement Disorders Center</s1><s2>Warwick, Rhode Island</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Rhode Island</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, Warren Alpert Medical School, Brown University</s1><s2>Rhode Island</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>The Norwegian Centre for Movement Disorders, Stavanger University Hospital</s1><s2>Stavanger</s2><s3>NOR</s3><sZ>2 aut.</sZ></inist:fA14><country>Norvège</country><wicri:noRegion>Stavanger</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Stavanger University Hospital</s1><s2>Stavanger</s2><s3>NOR</s3><sZ>2 aut.</sZ></inist:fA14><country>Norvège</country><wicri:noRegion>Stavanger</wicri:noRegion></affiliation></author><author><name sortKey="Hagell, Peter" sort="Hagell, Peter" uniqKey="Hagell P" first="Peter" last="Hagell">Peter Hagell</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Lund University Hospital</s1><s2>Lund</s2><s3>SWE</s3><sZ>3 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>Lund</wicri:noRegion></affiliation></author><author><name sortKey="Marinus, Johan" sort="Marinus, Johan" uniqKey="Marinus J" first="Johan" last="Marinus">Johan Marinus</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Neurology, Leiden University Medical Center</s1><s2>Leiden</s2><s3>NLD</s3><sZ>4 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Department of Psychiatry Johns Hopkins Hospital</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Department of Neurology, Johns Hopkins Hospital</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="09"><s1>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1><s2>Madrid</s2><s3>ESP</s3><sZ>6 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><inist:fA14 i1="11"><s1>Department of Neurological Sciences, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innshruck</s2><s3>AUT</s3><sZ>8 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Innshruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>ClinicalInvestigation Center INSERM CIC-9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Lahoratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa</s1><s3>PRT</s3><sZ>10 aut.</sZ></inist:fA14><country>Portugal</country><wicri:noRegion>Lahoratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa</wicri:noRegion></affiliation></author><author><name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name><affiliation wicri:level="2"><inist:fA14 i1="11"><s1>Department of Neurological Sciences, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1><s3>GBR</s3><sZ>12 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Department of Clinical Neurosciences, Institute of Neurology, University College London</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Fatigue</term><term>Force</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Recommendation</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Fatigue</term><term>Recommandation</term><term>Force</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Recommandation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was "recommended" if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of "recommended" differs from the use of this term in previous MDS task force scale reviews. "Suggested" scales failed to meet all the criteria of a "recommended" scale, usually the criterion of sensitivity to change in a study of PD. Scales were "listed" if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was "recommended" for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is "suggested" for both screening and severity. The Functional Assessment of Chronic Illness Therapy-Fatigue was "recommended" for screening and "suggested" for severity. The Multidimensional Fatigue Inventory was "suggested" for screening and "recommended" for severity. The Parkinson Fatigue Scale was "recommended" for screening and "suggested" for severity rating. The Fatigue Severity Inventory was "listed" for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was "listed" for screening and "suggested" for severity. Visual Analogue and Global Impression Scales are both "listed" for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>25</s2></fA05><fA06><s2>7</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease</s1></fA08><fA11 i1="01" i2="1"><s1>FRIEDMAN (Joseph H.)</s1></fA11><fA11 i1="02" i2="1"><s1>ALVES (Guido)</s1></fA11><fA11 i1="03" i2="1"><s1>HAGELL (Peter)</s1></fA11><fA11 i1="04" i2="1"><s1>MARINUS (Johan)</s1></fA11><fA11 i1="05" i2="1"><s1>MARSH (Laura)</s1></fA11><fA11 i1="06" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1></fA11><fA11 i1="07" i2="1"><s1>GOETZ (Christopher G.)</s1></fA11><fA11 i1="08" i2="1"><s1>POEWE (Werner)</s1></fA11><fA11 i1="09" i2="1"><s1>RASCOL (Olivier)</s1></fA11><fA11 i1="10" i2="1"><s1>SAMPAIO (Cristina)</s1></fA11><fA11 i1="11" i2="1"><s1>STEBBINS (Glenn)</s1></fA11><fA11 i1="12" i2="1"><s1>SCHRAG (Anette)</s1></fA11><fA14 i1="01"><s1>NeuroHealth, Parkinson's Disease and Movement Disorders Center</s1><s2>Warwick, Rhode Island</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Neurology, Warren Alpert Medical School, Brown University</s1><s2>Rhode Island</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>The Norwegian Centre for Movement Disorders, Stavanger University Hospital</s1><s2>Stavanger</s2><s3>NOR</s3><sZ>2 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neurology, Stavanger University Hospital</s1><s2>Stavanger</s2><s3>NOR</s3><sZ>2 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Neurology, Lund University Hospital</s1><s2>Lund</s2><s3>SWE</s3><sZ>3 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Neurology, Leiden University Medical Center</s1><s2>Leiden</s2><s3>NLD</s3><sZ>4 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Psychiatry Johns Hopkins Hospital</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="08"><s1>Department of Neurology, Johns Hopkins Hospital</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="09"><s1>Department of Psychiatry, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="10"><s1>Area of Applied Epidemiology, Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1><s2>Madrid</s2><s3>ESP</s3><sZ>6 aut.</sZ></fA14><fA14 i1="11"><s1>Department of Neurological Sciences, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>7 aut.</sZ><sZ>11 aut.</sZ></fA14><fA14 i1="12"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innshruck</s2><s3>AUT</s3><sZ>8 aut.</sZ></fA14><fA14 i1="13"><s1>ClinicalInvestigation Center INSERM CIC-9302 and Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="14"><s1>Lahoratório de Farmacologia Clínica e Terapêutica e Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa</s1><s3>PRT</s3><sZ>10 aut.</sZ></fA14><fA14 i1="15"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1><s3>GBR</s3><sZ>12 aut.</sZ></fA14><fA20><s1>805-822</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000193040220010</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>142 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0288337</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Fatigue has been shown to be a consistent and common problem in Parkinson's disease (PD) in multiple countries and cultures. It is one of the most disabling of all symptoms, including motor dysfunction, and appears early, often predating the onset of motor symptoms. Several studies of the epidemiology of fatigue have been published, often using different scales, but few on treatment. The Movement Disorder Society (MDS) commissioned a task force to assess available clinical rating scales, critique their psychometric properties, summarize their clinical properties, and evaluate the evidence in support of their use in clinical studies in PD. Six clinical researchers reviewed all studies published in peer reviewed journals of fatigue in PD, evaluated the scales' previous use, performance parameters, and quality of validation data, if available. Scales were rated according to criteria provided by the MDS. A scale was "recommended" if it has been used in clinical studies beyond the group that developed it, has been used in PD and psychometric studies have established that it is a valid, reliable and sensitive to change in people with PD. Requiring a scale to have demonstrated sensitivity to change in PD specifically rather than in other areas in order to attain a rating of "recommended" differs from the use of this term in previous MDS task force scale reviews. "Suggested" scales failed to meet all the criteria of a "recommended" scale, usually the criterion of sensitivity to change in a study of PD. Scales were "listed" if they had been used in PD studies but had little or no psychometric data to assess. Some scales could be used both to screen for fatigue as well as to assess fatigue severity, but some were only used to assess severity. The Fatigue Severity Scale was "recommended" for both screening and severity rating. The Fatigue Assessment Inventory, an expanded version of the Fatigue severity Scale, is "suggested" for both screening and severity. The Functional Assessment of Chronic Illness Therapy-Fatigue was "recommended" for screening and "suggested" for severity. The Multidimensional Fatigue Inventory was "suggested" for screening and "recommended" for severity. The Parkinson Fatigue Scale was "recommended" for screening and "suggested" for severity rating. The Fatigue Severity Inventory was "listed" for both screening and severity. The Fatigue Impact Scale for Daily Use, an adaptation of the Fatigue Impact Scale was "listed" for screening and "suggested" for severity. Visual Analogue and Global Impression Scales are both "listed" for screening and severity. The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Fatigue</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Fatigue</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Fatiga</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Recommandation</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Recommendation</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Recomendación</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Force</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Force</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Fuerza</s0><s5>11</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>186</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Autriche</li><li>Espagne</li><li>France</li><li>Norvège</li><li>Pays-Bas</li><li>Portugal</li><li>Royaume-Uni</li><li>Suède</li><li>États-Unis</li></country><region><li>Communauté de Madrid</li><li>Hollande-Méridionale</li><li>Illinois</li><li>Maryland</li><li>Midi-Pyrénées</li><li>Rhode Island</li><li>Texas</li><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li><li>Leyde</li><li>Madrid</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="États-Unis"><region name="Rhode Island"><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name></region><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name></country><country name="Norvège"><noRegion><name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name></noRegion><name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name></country><country name="Suède"><noRegion><name sortKey="Hagell, Peter" sort="Hagell, Peter" uniqKey="Hagell P" first="Peter" last="Hagell">Peter Hagell</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Marinus, Johan" sort="Marinus, Johan" uniqKey="Marinus J" first="Johan" last="Marinus">Johan Marinus</name></region></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name></region></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country><country name="France"><noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></noRegion></country><country name="Portugal"><noRegion><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000A58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:10-0288337
|texte= Fatigue Rating Scales Critique and Recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |